(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 18.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Ionis Pharmaceuticals's revenue in 2026 is $960,091,000.On average, 29 Wall Street analysts forecast IONS's revenue for 2026 to be $154,485,569,309, with the lowest IONS revenue forecast at $139,058,496,696, and the highest IONS revenue forecast at $172,540,723,600. On average, 29 Wall Street analysts forecast IONS's revenue for 2027 to be $201,019,935,700, with the lowest IONS revenue forecast at $134,257,001,463, and the highest IONS revenue forecast at $287,290,297,500.
In 2028, IONS is forecast to generate $272,967,418,900 in revenue, with the lowest revenue forecast at $185,031,606,100 and the highest revenue forecast at $387,050,812,400.